QCG
URGN icon

Quadrant Capital Group’s UroGen Pharma URGN Stock Holding History

Quadrant Capital Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-688
Closed -$12.4K – 2521
2026
Q1 		$12.4K Hold
688
– – ﹤0.01% 2143
2025
Q4 		$16.1K Hold
688
– – ﹤0.01% 2069
2025
Q3 		$13.7K Buy
+688
New +$12.4K ﹤0.01% 2071
2025
Q2 		– Sell
-1,340
Closed -$14.8K – 2561
2025
Q1 		$14.8K Buy
1,340
+1,314
+5,054% +$14K ﹤0.01% 2125
2024
Q4 		$277 Hold
26
– – ﹤0.01% 2687
2024
Q3 		$331 Hold
26
– – ﹤0.01% 2682
2024
Q2 		$437 Hold
26
– – ﹤0.01% 2637
2024
Q1 		$390 Sell
26
-30
-54% -$490 ﹤0.01% 2657
2023
Q4 		$840 Hold
56
– – ﹤0.01% 2571
2023
Q3 		$785 Hold
56
– – ﹤0.01% 2518
2023
Q2 		$580 Hold
56
– – ﹤0.01% 2555
2023
Q1 		$518 Sell
56
-41
-42% -$377 ﹤0.01% 2603
2022
Q4 		$860 Hold
97
– – ﹤0.01% 2569
2022
Q3 		$1K Sell
97
-104
-52% -$860 ﹤0.01% 2577
2022
Q2 		$2K Sell
201
-154
-43% -$1.06K ﹤0.01% 2285
2022
Q1 		$3K Buy
+355
New +$2.77K ﹤0.01% 2097
2021
Q4 		– Sell
-1,065
Closed -$18K – 2704
2021
Q3 		$18K Buy
1,065
+1,020
+2,267% +$16.2K ﹤0.01% 1306
2021
Q2 		$1K Sell
45
-16
-26% -$289 ﹤0.01% 2334
2021
Q1 		$1K Hold
61
– – ﹤0.01% 2307
2020
Q4 		$1K Buy
61
+46
+307% +$964 ﹤0.01% 2204
2020
Q3 		$0 Buy
+15
New +$340 ﹤0.01% 2313

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Quadrant Capital Group's URGN Position: Q2 2026 in Review

Quadrant Capital Group sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 688 shares — an estimated $12.4K sold.

Quadrant Capital Group first reported a position in URGN in Q3 2020 and held it in 21 quarters. The position peaked at $18K in Q3 2021. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Quadrant Capital Group reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 688 UroGen Pharma shares in Q2 2026, an estimated $12.4K.
  • Quadrant Capital Group first reported a position in UroGen Pharma in Q3 2020 and held it in 21 quarters.
  • Quadrant Capital Group's UroGen Pharma position peaked at $18K in Q3 2021.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.